Catalyst
Slingshot members are tracking this event:
Roche's (RHHBY) Rituxan Designated a Breakthrough Therapy by FDA for Pemphigus Vulgaris, a Rare Autoimmune Skin Disorder
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| RHHBY |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 24, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Rituxan, Fda, Pemphigus Vulgaris, Breakthrough Therapy
